- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04350970
High-flow Nasal Cannula and Exercise Tolerance in COPD
Acute Effects of High-flow Nasal Cannula and Non-invasive Ventilation on Constant-load Exercise Tolerance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The patients underwent an initial clinical examination, with anthropometric evaluation, blood gas analysis, pulmonary function tests and measurement of maximum respiratory pressures. The exercise protocol started in the sector of Ergometry and Cardiopulmonary Exercise Testing. After completing the maximum incremental cardiopulmonary exercise test, two additional visits were scheduled for the three constant load tests. All patients studied underwent an evaluation of cardiopulmonary exercise testing (CPET). During maximum-incremental CPET, breath by breath: oxygen consumption (V̇O2, mL/min), carbon dioxide production (V̇CO2, mL/min), respiratory exchange rate (RER), minute ventilation VE (L/min), respiratory rate (bpm), equivalent ventilation for O2 and CO2 (V̇E/V̇O2 and V̇E/V̇CO2). In addition, cardiac monitoring was performed by 12-lead electrocardiogram (ECG) throughout the procedure. On the day of the experiment, the patients underwent two cardiopulmonary exercises with constant-load at 90% of the previously determined peak, separated by an interval of at least 1 hour.
The NIV parameters were adjusted for each patient with Trilogy 100 (Philips™). Spontaneous ventilation mode was set before the protocol for all patients, and a previous period of NIV adaptation was performed to titrate the inspiratory and expiratory pressures. The adaptation period started with the minimum Inspiratory Positive Airway Pressure (IPAP) value of 15cmH2O, and, every 2 minutes, increasing the pressure every 2 cmH2O according to the patient's tolerance.16 The Expiratory Positive Airway Pressure (EPAP) was programmed to vary between 4 and 6 cmH2O. Before the start of the examination, an adaptation was performed with the selected mask and initial ventilator settings for 20 min. No additional oxygen was offered.
The high flow system used was Optiflow® (Fisher & Paykel Healthcare, Auckland, New Zealand). Before the test, flow titration was performed for the patient, which started with the administration of a minimum gas flow of 30L/min and, every 2 minutes, the flow was increased by 5L/min according to patient tolerance. The test only started after 20 minutes of adaptation.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
CE
-
Fortaleza, CE, Brasile, 60.430-370
- Federal University Of Ceara
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Previous COPD
- FEV1 ≤ 50%
- Optimized medication
Exclusion Criteria:
- COPD Exacerbation
- Cardiac disease
- Previous neurologic disorders
- Unable to complete all protocol
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Control
The cardiopulmonary exercise test was performed with patient breathing room air.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The control test was performed with no additional therapy.
|
Comparatore attivo: NIV
The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The NIV was used during all exercise test.
|
Comparatore attivo: HFNT
The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The high flow nasal therapy was used during all exercise test.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Exercise dinamic hyperinflation
Lasso di tempo: one week after all tests
|
To determine the dinamic hyperinflation during exercise test with 3-different situations , Control, NIV and HFNT.
During all testes the dinamic hyperinflation will be measured by inspiratory capacity (at rest and at the end o exercise test) and will be demonstrated as porcentage os maximum.
|
one week after all tests
|
Exercise Tolerance
Lasso di tempo: one week after all tests
|
To determine the exercise tolerance with 3-different situations , Control, NIV and HFNT.
Time of exercise test will be measured to determine which test could be the best for COPD patients.
In additional, the workload will (treadmill inclination and speed) be check to show which intervention has the better response.
|
one week after all tests
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Dyspnea
Lasso di tempo: one week after all tests
|
To determine the dyspnea during exercise test with 3-different situations , Control, NIV and HFNT.
After all situations, Borg scale will be performed to check the dyspnea score at the end of exercise.
|
one week after all tests
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 3.009.159
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Control
-
University of California, Los AngelesCompletatoDiabete di tipo 2Stati Uniti
-
Johns Hopkins UniversityCompletato
-
University of Southern CaliforniaPendulum TherapeuticsRitiratoDiabete di tipo 2 | Sintomi gastrointestinaliStati Uniti
-
Nephera Ltd.SconosciutoInsufficienza renale | Insufficienza cardiaca, congestizia | Scompenso cardiacoIsraele
-
Rethink Medical SLReclutamentoQualità della vita | Complicanza correlata al catetere | Infezione del tratto urinario associata a catetereSpagna
-
Rethink Medical SLRitiratoRitenzione urinaria | Complicazioni del catetere | Infezione del tratto urinario associata a catetereSpagna
-
Ulrike WillutzkiUniversity of BernReclutamentoDisordini mentali | Intervento onlineGermania
-
Icahn School of Medicine at Mount SinaiReclutamento
-
Devicare S.L.Clever Instruments S.L.; Fundacio PuigvertSconosciuto
-
Gonzalez-Heydrich, Joseph, M.D.Boston Children's Hospital; Harvard UniversityCompletatoLa rabbia | AggressioneStati Uniti